Patents by Inventor Simon Anthony HERBERT
Simon Anthony HERBERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240182431Abstract: The present invention relates to a new class of compounds of general formula (I), the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.Type: ApplicationFiled: March 14, 2022Publication date: June 6, 2024Applicants: Bayer Aktiengesellschaft, Bayer AktiengesellschaftInventors: Thomas BRUMBY, Jessica LOHRKE, Simon Anthony HERBERT, Olaf PANKNIN, Thomas FRENZEL, Claudia GREEN, Gregor JOST, Hubertus PIETSCH, Markus BERGER, Sven WITTROCK
-
Patent number: 11787797Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 28, 2021Date of Patent: October 17, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
-
Publication number: 20230201186Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 30, 2022Publication date: June 29, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, Dennis KIRCHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, Dirk KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230148194Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: May 11, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230113037Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 10, 2020Publication date: April 13, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
-
Publication number: 20230062100Abstract: The present invention covers aminoquinolone compounds of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, X and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Julien LEFRANC, Rienk OFFRINGA
-
Publication number: 20230013419Abstract: The present invention covers P2X3 inhibitor compounds of general formula (I) in which R1 and R2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 25, 2020Publication date: January 19, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Antje ROTTMANN, Oliver Martin FISCHER, Kai THEDE, Simon Anthony HERBERT, Ursula GANZER, Andrea ROTGERI, Elisabeth POOK
-
Patent number: 11524938Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: GrantFiled: October 9, 2020Date of Patent: December 13, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Stefan Werner, Stefanie Mesch, Arwed Cleve, Nico Bräuer, Simon Anthony Herbert, Markus Koch, Henrik Dahllöf, Maren Osmers, Elizabeth Hardaker, Anton Lishchynskyi
-
Publication number: 20220324807Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: ApplicationFiled: October 9, 2020Publication date: October 13, 2022Applicant: Bayer Pharma AktiengesellschaftInventors: Stefan WERNER, Stefanie MESCH, Arwed CLEVE, Nico BRÄUER, Simon Anthony HERBERT, Markus KOCH, Henrik DAHLLÖF, Maren OSMERS, Elizabeth HARDAKER, Anton LISHCHYNSKYI
-
Publication number: 20220226279Abstract: The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6? Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.Type: ApplicationFiled: April 20, 2020Publication date: July 21, 2022Inventors: Léa Aurelie Bouché, Daniel Korr, Antonius ter Laak, Ernesto Amaury Fernandez-Montalvan, Naomi Barak, Roman Hillig, Roland Neuhaus, Matyas Gorjanacz, Vera Pütter, Stefan Niklaus Gradl, Simon Anthony Herbert, Steven James Ferrara, Craig Strathdee, Jacob Jaffe
-
Publication number: 20210188846Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 28, 2021Publication date: June 24, 2021Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MUELLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Simon Anthony HERBERT, Claudia MERZ, Michael NIEHUES, Carl Friedrich NISING, Martina SCHÄFER, Katja ZIMMERMANN, Jörg KNÄBLEIN, Kai THEDE, Thomas FAUPEL
-
Patent number: 10968216Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 25, 2017Date of Patent: April 6, 2021Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
-
Patent number: 10844016Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: GrantFiled: April 26, 2017Date of Patent: November 24, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Stefan Werner, Stefanie Mesch, Arwed Cleve, Nico Bräuer, Simon Anthony Herbert, Markus Koch, Henrik Dahllöf, Maren Osmers, Elizabeth Hardaker, Anton Lishchynskyi
-
Patent number: 10717749Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: September 26, 2016Date of Patent: July 21, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
-
Patent number: 10660334Abstract: The invention relates to novel compounds of the formula (I) in which Aa, Ab, Ac, Ad, R1, Q and n have the definitions given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.Type: GrantFiled: August 9, 2017Date of Patent: May 26, 2020Assignees: Bayer CropScience Aktiengesellschaft, Bayer AktiengesellschaftInventors: Laura Hoffmeister, Rüdiger Fischer, Dominik Hager, Nina Kausch-Busies, Marc Mosrin, David Wilcke, Matthieu Willot, Kerstin Ilg, Ulrich Goergens, Simon Anthony Herbert, Anton Lishchynskyi, Andreas Turberg, Anthony Millet
-
Publication number: 20190375747Abstract: The present invention provides triazolone compounds compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 25, 2017Publication date: December 12, 2019Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus GRADL, Duy NGUYEN, Knut EIS, Judith GÜNTHER, Timo STELLFELD, Andreas JANZER, Sven CHRISTIAN, Thomas MUELLER, Sherif El SHEIKH, Han Jie ZHOU, Changjia ZHAO, David B. SYKES, Steven James FERRARA, Kery LIU, Simon Anthony HERBERT, Claudia MERZ, Michael NIEHUES, Carl Friedrich NISING, Martina SCHÄFER, Katja ZIMMERMANN, Jörg KNÄBLEIN, Kai THEDE, Thomas FAUPEL
-
Publication number: 20190313643Abstract: The invention relates to novel compounds of the formula (I) in which Aa, Ab, Ac, Ad, R1, Q and n have the definitions given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.Type: ApplicationFiled: August 9, 2017Publication date: October 17, 2019Applicants: Bayer CropScience Aktiengesellschaft, Bayer AktiengesellschaftInventors: Laura HOFFMEISTER, Rüdiger FISCHER, Dominik HAGER, Nina KAUSCH-BUSIES, Marc MOSRIN, David WILCKE, Matthieu WILLOT, Kerstin ILG, Ulrich GOERGENS, Simon Anthony HERBERT, Anton LISHCHYNSKYI, Andreas TURBERG, Anthony MILLET
-
Patent number: 10271552Abstract: The present application relates to thiadiazole compounds, compositions containing such compounds, their use for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for the preparation of the thiadiazole compounds.Type: GrantFiled: July 5, 2016Date of Patent: April 30, 2019Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Hans-Georg Schwarz, Anne Decor, Joerg Greul, Axel Trautwein, Eike Kevin Heilmann, Reiner Fischer, Peter Loesel, Olga Malsam, Daniela Portz, Kerstin Ilg, Herbert Sommer, Sascha Eilmus, Melanie Scharwey, Anton Lishchynskyi, Sven Geibel, Ulrich Goergens, Simon Anthony Herbert, Andreas Turberg
-
Publication number: 20190119210Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: ApplicationFiled: April 26, 2017Publication date: April 25, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Stefan WERNER, Stefanie MESCH, Arwed CLEVE, Nico BRÄUER, Simon Anthony HERBERT, Markus KOCH, Henrik DAHLLÖF, Maren OSMERS, Elizabeth HARDAKER, Anton LISHCHYNSKYI
-
Publication number: 20180273548Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: September 26, 2016Publication date: September 27, 2018Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich LÜCKING, Jens GEISLER, Daniel HOG, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Kunzeng ZHENG, Ping GAO, Gang CHEN, Jiajun XI, Simon Anthony HERBERT, Gerhard SIEMEISTER, Nicolas WERBECK